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Abstract
Background: IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, affecting close to a
million people. Circulating galactose-deficient IgA (gd-IgA), present in patients with IgAN, form immune complex
deposits in the glomerular mesangium causing local proliferation and matrix expansion. Intriguing though,
individuals having gd-IgA deposits in the kidneys do not necessarily have signs of glomerular disease. Recurrence of
IgAN only occurs in less than half of transplanted patients with IgAN, indicating that gd-IgA is not the only factor
driving the disease. We hypothesize that, in addition to IgA complexes, patients with IgAN possess a subtype of
mesangial cells highly susceptible to gd-IgA induced cell proliferation.
Methods: To test the hypothesis, we designed a technique to culture primary mesangial cells from renal biopsies
obtained from IgAN patients and controls. The cell response to gd-IgA treatment was then measured both on gene
and protein level and the proliferation rate of the cells in response to PDGF was investigated.
Results: When treated with gd-IgA, mesangial cells from patients with IgAN express and release more PDGF
compared to controls. In addition, the mesangial cells from patients with IgAN were more responsive to treatment
with PDGF resulting in an increased proliferation rate of the cells compared to control. Mesangial cells cultured
from patients with IgAN expressed and released more IL-6 than controls and had a higher expression of matrix
genes. Both mesangial cells derived from patients with IgAN and controls increased their expressed TGFβ1 and
CCL5 when treated with gd-IgA.
Conclusion: We conclude that mesangial cells derived from IgAN patients have a mesangioproliferative phenotype
with increased reactivity to IgA and that these cellular intrinsic properties may be important for the development of
IgA nephropathy.
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Background
IgA nephropathy (IgAN) is the most common type of
glomerular nephritis worldwide. For a long time it
has been considered rather benign, but between 30
and 50 % of the patients will eventually develop
dialysis-dependent chronic kidney disease [1]. Some
patients with morphological signs of IgAN also have
IgA vasculitis (IgAV, formerly named Henoch Schön-
lein purpura) [2, 3]. Patients with IgAN have
galactose-deficient IgA (gd-IgA) in their circulation.
The gd-IgA easily forms large immune-complexes,
which are deposited in the mesangium [4]. These de-
posits are a key feature of the disease, together with
mesangial proliferation and an expanded mesangial
matrix, and are used for histopathological diagnosis of
IgAN [5]. Several growth factors and cytokines have
been suggested to be involved in the proliferation and
expansion of the mesangial matrix, most notably
PDGF and TGFβ1 [6]. Investigation of PDGFB gene
expression in IgAN has shown that there is an
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increase of PDGFB in patients with IgAN [7], and
stimulation of mesangial cells in vitro with PDGF in-
creases their expression of several cytokines and
growth factors such as IL-6 and TGFβ1 [8]. IL-6 is a
cytokine known to increase in mesangial cells when
stimulated with gd-IgA. It has been suggested to be a
prognostic marker for IgAN, but its role is still de-
bated [9, 10] Data showing that the complement sys-
tem (alternative and lectin-pathways) are of
importance in IgAN are also accumulating [11]. How-
ever, the molecular mechanisms behind the highly
variable onset and progression of these glomerular
diseases are still elusive. There are familial forms of
IgAN [12, 13] where gd-IgA is found in the circula-
tion of asymptomatic relatives. A Finnish investigation
of kidneys from suicide or trauma victims revealed
that 6.8 % of the kidneys contained IgA depositions
although they had no other signs of disease. In a Jap-
anese study of healthy kidney donors, 16.1 % of the
investigated kidneys contained IgA deposits [14, 15].
However it is not known if these deposits contain gd-
IgA. Indeed, 60 % of transplanted patients diagnosed
with IgAN develop deposits in their kidney graft.
[16–19] However, the clinical disease recurs in less
than half (22–33 %) of the transplanted patients [20–
22]. Based on these facts, we wanted to investigate
the role of the mesangial cells in development of
IgAN. Since there is no specific way to evoke IgAN
in cell culture and existing animal models are debated
we developed a technique to culture mesangial cells
from glomeruli retrieved directly from patient biop-
sies. Cells were either stimulated with purified IgA1
from IgAN patients (gd-IgA) or with IgA1 from healthy
subjects (cIgA). Gene expression levels of cytokines,
growth factors and matrix molecules and release of cyto-
kines and growth factors into the cell medium were inves-
tigated as well as the proliferative response to PDGF. We
were able to demonstrate that mesangial cells from pa-
tients with IgAN are significantly more reactive to IgA1
and PDGF stimulation and the cells express and produce




This study was conducted in accordance with the declar-
ation of Helsinki and with the approval of the regional
ethical review board of Gothenburg. All patients in-
cluded in the study signed a written informed consent.
Six patients with IgA deposits were used as sources of
primary mesangial cell cultures (MCs), age 33 ± 15,
eGFR 56 ± 27, male to female ratio 5:1, see Table 1. As
controls, we used commercially available primary MCs
from two healthy donors (Lonza, Basel, Switzerland), age
46 ± 9, male to female 1:1, and cells cultured from a
male patient with thin glomerular basement membrane
disease (TGBM), age 44 with normal renal function.
Three patients with IgAN and three healthy subjects do-
nated 50 ml of blood each used for purification of IgA1.
Mesangial cell culture from renal biopsies
At the time of routine renal biopsy, newly taken biopsies
were submerged in ice-cold PBS and loosely attached
glomeruli were collected from each biopsy. The glom-
eruli were transferred by pipetting to cell culture plates
coated with attachment factor (Cascade biologics) and
cultured in DMEM F12 ham’s medium (Lonza, Basel,
Switzerland) supplemented with antibiotics (Lonza) and
20 % human serum. After 10–20 days of incubation,
MCs were seen at the edges of the glomeruli that at-
tached to the plate and were subcloned to new cell cul-
ture plates without attachment factor. The medium was
switched to DMEM F12 supplemented with 20 % FBS
(Thermo Scientific, Waltham, MA) and 1 % antibiotics
(Lonza). In Fig. 1, the novel technique of harvesting and
culturing human mesangial cells from renal biopsies is
schematically illustrated (Fig. 1a) and a glomerulus with
mesangial cells growing out is shown (Fig. 1b). Cells
were identified as MCs by morphology, negative staining
for the endothelial marker Ulex Europaeus Agglutinin I
(Vector laboratories, Burlingame, Ca) 1:100 and the
podocyte marker synaptopodin (Abcam, Cambridge,
UK). Positive staining was seen for the mesangial marker
smooth muscle actin 1:100 (Abcam), see Fig. 1c and d.
Table 1 Clinical data for patients used for mesangial cell culture
Morphological diagnosis Sex Age Cr-EDTA Clearance Creat U-Alb/Creat Progress (ml/min/year) BP BP medication Immuno-suppression
IgA Nephropathy M 66 64 98 303 −8.19 138/88 Yes No
IgA Nephropathy M 25 21 305 243 −7.54 125/65 No No
IgA Nephropathy M 31 214 17 −14.30 115/70 No No
IgA Nephropathya M 24 98 80 22 6.84 120/50 Yes No
IgA Nephropathya M 24 110 94 11 −0.48 120/70 No Yes
IgA Nephropathya F 27 126 −29.37 120/70 No No
a Clinical diagnosis IgA Vasculitis (Henoch Schönlein Purpura)
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IgA1 purification
Total IgA1 was isolated from the sera of patients and
controls using jacalin conjugated to agarose (Vector) as
described previously [23]. The identity of the purified
IgA1 was confirmed by HPLC where peaks with mono-
meric, dimeric and polymeric IgA1 were detected, Fig. 1e.
The fraction containing the polymeric IgA1 is often re-
ferred to as gd-IgA containing immune-complexes and
antiglycan antibodies. To confirm that the ratio of gal-
actose deficient IgA1 was higher in patient samples than
control samples a sandwich ELISA using the lectin from
helix aspersa (Sigma Aldrich, Saint Louis, MO) was used
[24]. This confirmed that the IgA1 purified from patients
with IgAN had a higher content of galactose deficient
IgA1 than the healthy controls, Fig.1f. The concentra-
tion of the purified IgA1 was measured using
nephelometry.
Mesangial cell gene expression experiments
Primary MCs obtained from patients with IgAN and
controls were cultured in DMEM Ham’s F12 supple-
mented with 20 % FBS and 1 % antibiotics and used for
experiments at passage 5–8. Before treatment all cells
were starved in medium containing 0.5 % FBS overnight.
Cells were then stimulated with cIgA1 (IgA1 from
healthy controls) or gd-IgA1 (IgA1 from patients with
Fig. 1 Mesangial cells were cultured from renal biopsies, characterized and treated with IgA. Schematic figure of harvest and culture of mesangial
cells (a). Mesangial cells growing out from glomeruli (b). Immunofluorescence microscopy of smooth muscle actin labeling in mesangial cells.
Smooth muscle actin is exclusively localized to the mesangial cells in the glomeruli. Mesangial cells cultured from glomeruli from renal biopsies
were stained using an anti-smooth muscle actin antibody (green). Nuclei are stained blue with DAPI. Magnification 20× (c), 40× (d). The mesangial
cells were negative for endothelial and podocyte markers, see Methods. IgA1 purified from human blood was run on HPLC to detect different
sizes of IgA1 (e). A representative sandwich ELISA shows that IgA1 purified from patients with IgAN have a higher amount of gd-IgA than IgA1
purified from controls (f)
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IgAN), 100 μg/ml, in starvation medium for 6 h before
harvest. Cells were lysed with RLT buffer (Qiagen, Venlo,
Netherlands) and RNA was extracted with RNeasy Plus
Mini kit using the QIAcube (Qiagen). Concentration
and quality of the RNA was determined using the
StdSense kit on the Experion (BIO-RAD, Hercules, CA)
and/or Nanodrop 2000 (Thermo Scientific). Reverse
transcription of the RNA for Q-PCR was performed
using High capacity RNA to cDNA kit™ (Applied Biosys-
tems, Foster City, CA). The reaction was carried out
using PTC-200 Peltier Thermal cycler (Bio-Rad). The
mRNA levels were quantified by real time PCR per-
formed on the ViiA 7 Real-Time PCR system (Applied
Biosystems) using custom Taqman® Array 384-well cards
(Applied Biosystems) with a gene set of 23 genes in du-
plicate and GAPDH as housekeeping gene.
Release of growth factors and cytokines from mesangial
cells
Primary IgAN MCs and control MCs were cultured as
previously described (passage 5–8) to 80 % confluency
and starved overnight and then stimulated with starva-
tion medium containing either cIgA1 or gd-IgA1
(100 μg/ml) for 24 h. Medium was collected and ana-
lysed on Bio-Plex 200 system (BIO-RAD) using the 27
human Bio-Plex Pro Assays for cytokines, chemokines
and growth factors (BIO-RAD) and run according to the
manufacturer's protocol. In addition to IgAN MCs, both
mesangial cell cultures from TGBM and primary con-
trols were stimulated for 6 h and the medium analysed
with a Bio-Plex for PDGF-BB. Release of TGFβ1 from
IgAN MCs after 6 h of stimulation was also analysed
using a Bio-Plex for TGFβ1.
Proliferation assay of mesangial cells
Primary MCs from patients with IgAN or TGBM (con-
trol) were seeded in 96 well plates (5000 cells/well, pas-
sage 5–8). Cells were starved overnight and then
stimulated with 50 ng/ml of either PDGF-BB or PDGF-
AB (R&D Systems, Minneapolis, MN) for 20 h before
starting the BrdU proliferation assay (Roche) that was
run according to the manufacturer's protocol. Incorpor-
ation of BrdU was measured using SpectraMax i3
(Molecular Devices, Sunnyvale, CA).
Statistics
For gene expression studies and release of cytokines one
way Anova with multiple comparisons with Bonferroni
correction was used. For statistics of proliferation rate
and ratio of gd-IgA student’s t-test was used. Data is
presented as mean ± SEM except for results from prolif-
eration experiments that are presented as min and max.
P < 0.05 was considered statistically significant.
Results
IgAN mesangial cells exhibit gd-IgA induced PDGF
expression and increased sensitivity to PDGF
IgAN patients have shown increased PDGFB expression
[7] and we thereby investigated if PDGFB expression
was altered in IgAN MCs following stimulation with gd-
IgA. We found that a 6 h stimulation with gd-IgA sig-
nificantly increased the gene expression of PDGFB (gene
coding for platelet derived growth factor subunit B)
compared to untreated IgAN MCs, see Fig. 2a. The con-
trol cells did not alter their gene expression of PDGFB
in response to either treatment. The gene expression of
the receptor PDGFRB (gene coding for platelet-derived
growth factor receptor beta) was not affected when stim-
ulated with IgA in any of the cells, and the expression of
the receptor was significantly lower in the IgAN MCs
than in the control MCs independent of treatment, see
Fig. 2b. To confirm the altered expression on protein
level, PDGF levels was investigated by measuring the re-
lease of PDGF-BB into the cell culture medium after 6
and 24 h of stimulation with cIgA or with gd-IgA, Fig. 2c
and d. Both the IgAN MCs and control MCs responded
with significant increases in the release of PDGF-BB
when stimulated with gd-IgA for 6 or 24 h but the
amount released by the IgAN MCs after gd-IgA stimula-
tion was significantly higher than the amount released
by the control MCs. In addition, similar results as in
Fig. 2c and d were obtained using the control mesangial
cells from a patient diagnosed with TGBM. Significant
differences were observed between untreated and gd-IgA
for both groups of cells (control; untreated 10.5 ± 0.1,
gd-IgA 29.9 ± 4.5, P < 0.001, IgAN; untreated 0.72 ± 1.8,
gd-IgA 58.0 ± 3.8, P < 0.001). There was also significantly
higher release of PDGF-BB for IgAN MCs treated with
gd-IgA compared to TGBM MCs (P < 0.001).
To investigate how the mesangial cells from IgAN pa-
tients responded to the increase in PDGF synthesis and
release, cells were stimulated with PDGF-AB and BB
and a proliferation assay was performed using BrdU
(Fig. 2e). Interestingly, the IgAN MCs were more react-
ive in their proliferative response to PDGF than the con-
trol cells (TGBM). These results show that mesangial
cells derived from patients with pathogenic IgA deposits
both produce more PDGFB and are more sensitive to
PDGFB than control MCs.
IgA increases IL-6 expression in mesangial cells
Since gd-IgA increases PDGF expression in IgAN MCs,
which from previous studies is known to increase IL-6
in mesangial cells [8] we tested if gd-IgA could increase
IL-6 in IgAN MCs. IgAN MCs and control MCs were
stimulated with gd-IgA or cIgA. All of the IgAs tested
resulted in a significant increase of IL-6 gene expression
in IgAN MCs and controls, Fig. 3a. In addition, to test if
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Fig. 2 (See legend on next page.)
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the IL-6 secretion from IgAN MCs cells was altered
when compared to control MCs, release of IL-6 into the
medium was analysed and both IgAN MCs and control
MCs were shown to release significantly more IL-6 when
stimulated with gd-IgA. Interestingly, the release of IL-6
was significantly higher in the IgAN MCs in response to
gd-IgA than in the control MCs, see Fig. 3b.
The gene expression of TGFB1 is increased in mesangial
cells when exposed to gd-IgA
PDGF has previously been shown to increase the expres-
sion of the growth factor TGFβ1 in mesangial cells, and
by doing so induce an expansion of the mesangial matrix
[6]. We therefore investigated if MCs exposed to gd-IgA
increased the gene expression of TGFB1 (gene coding
for TGFβ1) both in IgAN MCs and control MCs and
compared to their respective untreated control, Fig. 4a.
We found that the gene expression of TGFB1 was sig-
nificantly increased in IgAN MCs after treatment with
gd-IgA, and the same trend was found in the controls
but not to significant levels. The expression of the recep-
tor TGFBR1 was not significantly affected by stimulation
with any IgA1 in either group of cells, see Fig. 4b. We
also measured the release of TGFβ1from the IgAN MCs
and found that treatment with either cIgA or gd-IgA in-
creased the release of TGFβ1 into the cell culture
medium, see Fig. 4c.
gd-IgA increased the release of CCL5 (RANTES) by
mesangial cells
It has been reported that the level of proteinuria in pa-
tients with IgAN correlates to intrarenal levels of CCL5
(also known as RANTES) [25]. To investigate if CCL5
levels are increased in IgAN MCs the release of CCL5
was studied in the presence of gd-IgA and cIgA. A pro-
nounced increase of CCL5 was found in both IgAN
MCs and control MCs following gd-IgA exposure and
conversely cIgA did not trigger a CCL5 response,
(See figure on previous page.)
Fig. 2 PDGF is the major growth factor for mesangial cells we therefore wanted to investigate the expression of PDGF in mesangial cells from
controls or patients with IgA deposits as well as their response to stimulation with PDGF. Mesangial cells (MCs) from patients with IgA
nephropathy (IgAN) and controls were stimulated with IgA1 purified from blood from healthy controls (cIgA) or patients with IgAN (gd-IgA) or
medium only for 6 h and the gene expression was investigated. The gene expression of PDGFB was not affected for the control MCs when
stimulated with either cIgA or gd-IgA. The gene expression of PDGFB was increased for the IgAN MCs when stimulated with either cIgA or
gd-IgA and stimulation of gd-IgA on IgAN MCs had a significantly higher expression than in control MCs stimulated with gd-IgA (a). In contrast
the gene expression of PDGFRB (gene coding for platelet-derived growth factor receptor beta) was lower in all samples from IgAN MCs compared
to the control MCs, but the gene was not further affected by stimulation with either cIgA or gd-IgA (b). Medium was collected from IgAN MCs
and control MCs after 6 and 24 h of stimulation with cIgA and gd-IgA and the release of PDGF-BB into the medium was measured. Both the IgAN
MCs and control MCs released the highest amounts of PDGF-BB when stimulated with gd-IgA, but the levels was significantly higher for the IgAN
MCs than for the control-MCs after 6 h (c) and 24 h (d). Mesangial cells from patients with IgAN and control were treated with 50 ng of either
PDGF-AB or -BB or medium only and the relative proliferation of the cells was measured. Stimulation of the IgAN MCs with PDGF gave a
significant increase of the relative proliferation compared to control MCs (e). Grey bars represent control MCs, black bars represent IgAN MCs
*P < 0.05, **P < 0.01, **P < 0.001. Error bars in (a), (b), (c) and (d) represent SEM and in D min to max, + represents mean
Fig. 3 Gene expression and release of IL-6. IL-6 expression is known to increase in mesangial cells when stimulated with gd-IgA and has been
suggested as a prognostic marker for IgAN but its role is still debated. Mesangial cells (MCs) from patients with IgA nephropathy (IgAN) and
controls were stimulated with IgA1 purified from blood from healthy controls (cIgA) or patients with IgAN (gd-IgA) or medium only for 6 h and
the gene expression was investigated. Stimulation with IgA on both controls MCs and IgAN MCs increased the gene expression of IL-6 in a similar
pattern (a). The release of IL-6 into the medium after 24 h of stimulation was most pronounced for the gd-IgA treatment for both groups of cells,
but the IgAN MCs released significantly more IL-6 than the control MCs stimulated with gd-IgA (b). Grey bars represent control MCs, black bars
represent IgAN MCs * P < 0.05, ** P < 0.01, ***P < 0.001, error bars represent SEM
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Fig. 5a. In contrast, other chemokines such as IL-8
and MCP-1 was shown to be elevated solely in con-
trol MCs already at baseline with increased levels fol-
lowing gd-IgA incubation, see Fig. 5b and c. Intriguingly,
the IgAN MCs did not change their release of these cyto-
kines either in response to cIgA or gd-IgA. The other cy-
tokines, chemokines and growth factors included in the
assay (see manufactures information about Bio-Plex Pro
Human 27-plex, BIO-RAD) were either expressed at very
low levels or/and did not respond to stimulation with
cIgA nor gd-IgA for any of the mesangial cells.
IgAN MCs have an increased expression of matrix-
associated genes compared to controls
To further study alteration in matrix components in IgAN
MCs, the expression of the matrix genes: BGN (biglycan),
COL4A1 (collagen alpha-1(IV) chain), DCN (decorin),
FN1 (fibronectin), HSPG2 (perlecan) and NDST1 (hepa-
ran sulfate N-deacetylase/N-sulfotransferase 1) was ana-
lysed and found to be elevated in IgAN MCs when
compared to control MCs. The elevation of matrix genes
was still found to be present in IgAN MCs when cIgA and
gd-IgA was added to the cultures, see Fig. 6.
Discussion
In this study, we have shown that it is possible to harvest
and to culture primary mesangial cells from renal biop-
sies patients with for example IgAN and to study those
cells in vitro. Our hypothesis was that the mesangial cell
(MC) from patients with IgAN are hyperresponsive to
gd-IgA and more prone to proliferation than mesangial
cells from individuals without kidney disease. The results
obtained support our hypothesis and may at least partly
explain why renal IgA deposits only develop into ne-
phropathy in a subset of the human population. It is
noteworthy, that the phenotype of the IgAN MC display
only subtle differences compared to the MCs from
healthy controls, which is fitting for a disease that pro-
gresses slowly over years or even decades.
Fig. 4 Gene expression of TGFB1 and TGFBR1 and release of TGFβ1. Mesangial cells (MCs) from patients with IgA nephropathy (IgAN) and
controls were stimulated with IgA1 purified from blood from healthy controls (cIgA) or patients with IgAN (gd-IgA) or medium only for 6 h and
the gene expression was investigated. Stimulation of control MCs and IgAN MCs with gd-IgA gave a significant increase in the gene expression
of TGFB1 (gene coding for TGFβ1) (a). The gene expression for TGFBR1 (gene coding for TGF-beta receptor type-1) was not significantly affected
by any of the treatments (b). IgAN MCs were stimulated with either cIgA or gd-IgA for 6 h and the release of TGFβ1into the cell culture medium
was investigated. Both treatment with cIgA and gd-IgA resulted in an increased release of TGFβ1 compared to untreated cells (c). Grey bars
represent control MCs, black bars represent IgAN MCs * P < 0.05, ** P < 0.01, ***P < 0.001, error bars represent SEM
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As outlined in the Introduction, IgAN recurs histo-
logically in at least 60 % of transplanted patients [16]
and it develops into clinically significant nephropathy
in 20–35 % of all transplanted IgAN patients [20–22].
In a study of 38 kidney transplant patients with
recurrence of IgAN, 22 without and 17 healthy con-
trols, the risk of recurrence correlated with the levels
of the following three biomarkers: gd-IgA, IgG auto-
antibodies against gd-IgA and soluble CD89 [26].
However, it is still unknown how these biomarkers
Fig. 5 Release of CCL5, IL-8 and MCP-1. Mesangial cells (MCs) from patients with IgA nephropathy (IgAN) and controls were stimulated with IgA1
purified from blood from healthy controls (cIgA) or patients with IgAN (gd-IgA) or medium only for 24 h and the release of cytokines into the
medium was investigated. Stimulation of control MCs and IgAN MCs with gd-IgA resulted in an increased release of CCL5 in both groups of cells,
in contrast stimulation with cIgA did not affect either group of cells at all (a). Only the control MCs responded to treatment with gd-IgA with an
increased release of IL-8 (b) and MCP-1 (c). Grey bars represent control MCs, black bars represent IgAN MCs * P < 0.05, ** P < 0.01, ***P < 0.001,
error bars represent SEM
Fig. 6 Gene expression of matrix associated genes. One of the main findings in IgAN is expanded mesangial matrix and mesangial proliferation.
In order to investigate if cells from patients with IgA-depositions in the kidney express more matrix associated genes we investigated the gene
expression of selected matrix genes, namely; BGN (biglycan), COL4A1 (collagen alpha-1(IV) chain), DCN (decorin), FN1 (fibronectin), HSPG2
(perlecan) and NDST1 (heparan sulfate N-deacetylase/N-sulfotransferase 1). The expression of DCN (a small proteoglycan) was significantly higher
in untreated IgAN MCs than controls. Overall we could see a trend that IgAN MCs had a higher expression of matrix genes, in the unstimulated
groups, and that stimulation with cIgA and gd-IgA increased the expression for all groups. * P < 0.05, ** P < 0.01, ***P < 0.001, error bars
represent SEM
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may be involved in the onset and progression of
IgAN.
In order to further understand the mechanisms behind
onset of IgAN we developed a technique to culture pri-
mary mesangial cells from human renal biopsies since
there is a lack of good in vitro and in vivo models for
the disease. Culturing mesangial cells from biopsies is
not trivial since the renal tissue is sparse and the glom-
eruli are badly needed for the morphological diagnosis.
It is known however, that with each needle biopsy, there
are 3–6 glomeruli that are cut loose. By dipping the bi-
opsy needle in cold saline before processing the biopsy
tissue core, these glomeruli (that otherwise would be
wasted) can be harvested and placed (cut or uncut) on
Petri dishes. Using proper culturing media, mesangial
cells can be selected isolated and cultured. Since these
cells are primary cultures in a low passage, they are
likely to maintain their distinct phenotype. The draw-
back is that primary clones will stop growing and/or
change their phenotype after a finite number of passages
compared to for instance immortalized cells. Another
limitation is that it is not possible to culture mesangial
cells from all patients, which may introduce a selection
bias. A third limitation is that active inflammation may
alter the glomerular mesangial cell phenotype per se. It
is however likely that the latter effect is “washed out”
during the inflammatory-free culturing process hence re-
storing the mesangial cell to its “control state”.
We investigated gene and protein expression of several
known inducers of proliferation and matrix expansion in
mesangial cells from IgAN patients and from controls.
We also conducted functional assays to assess prolifera-
tion of these cells with and without stimulation with IgA
purified from patients diagnosed with IgAN (gd-IgA) or
from healthy controls (c-IgA). Stimulation of mesangial
cells from patients with IgAN with gd-IgA significantly
increased the gene expression of PDGFB, while the con-
trol MCs did not. Moreover, IgAN MCs released signifi-
cantly more PDGF-BB than control MCs when
stimulated with gd-IgA confirming the gene expression
data. PDGF-BB has a proliferative and matrix expanding
effect on mesangial cells both in vitro and in vivo [27, 28],
and such an autocrine effect has previously been estab-
lished for MCs. However, not only did the IgAN MCs pro-
duce more PDGF, the cells responded to PDGF
stimulation with a higher proliferation rate than con-
trol MCs. Thus, IgAN MCs are more sensitive to gd-
IgA stimulation, produce more PDGF and are more
sensitive to PDGFB. These intrinsic properties of the
IgAN MCs contribute to the increased proliferation
and matrix expansion that is a hallmark of IgAN.
TGFβ1 is another growth factor known to be involved
in IgAN and shown to be up-regulated in IgA treated
mesangial cells [29]. We could confirm the finding of
Lai et al. in IgAN MCs as well as in control MCs. IL-6
has also been suggested to be a part of the pathogenesis
of IgAN and gd-IgA has been shown to increase the
gene expression of IL-6 [23], but the effect of cIgA on
mesangial cells IL-6 expression was not investigated in
that study. Mesangial cells also produce CCL5 [30], and
the levels of intrarenal gene expression of CCL5 seem to
correlate to the level of proteinuria in patients with
IgAN [25]. In our hands, all mesangial cells (IgAN and
control) increase their expression either on the gene or
protein level of TGFβ1, IL-6 and CCL5 in response to
cIgA and gd-IgA. In contrast MCP-1 and IL-8 were only
upregulated in the control MCs. We hypothesise that
TGFβ1, IL-6 and CCL5, are not part of the unique MC
phenotype of IgAN patients, but rather constitute a gen-
eral MC response to IgA.
Among the investigated matrix genes we only found a
significant upregulation of the gene expression for dec-
orin but could see a clear trend that IgAN derived MCs
have an increased level of expression of matrix genes. In
an animal model of glomerulonephritis that is induced
by injection of anti-thymocyte serum in rats Okuda et al.
showed that increased TGFβ1 expression was coupled to
increased production of proteoglycans and glomerular
matrix accumulation [31] and involvement in IgAN has
been suggested by us and others [32, 33]. Decorin is a
small proteoglycan known to be a natural inhibitor for
TGFβ1 and in previous studies we have shown that both
TGFβ1 and decorin have increased gene expression in
glomeruli from patients with IgAN [33]. In that study,
we showed that the proteoglycan perlecan (gene HSPG2)
is up-regulated in glomeruli from patients with IgAN,
both on the mRNA and the protein level. Heparan sul-
fate proteoglycans can bind several growth factors, in-
cluding PDGF-BB for which the interaction governs
tissue distribution and possibly also the bioavailability of
the growth factor [34, 35]. In this paper, however, the in-
crease in perlecan gene expression did not reach statis-
tical significance.
Mechanisms behind IgA nephropathy – the triple hit
hypothesis
The results of the present study give us confidence to
propose a revision of the current theory of how IgAN
develops and progresses. The first requirement is the
presence of gd-IgA and IgG autoantibodies against IgA
forming IgA-complexes that forms deposits in the
mesangium of the kidneys. Second, the individual must
have mesangial cells with a IgAN-prone phenotype, i.e.
increased production of PDGF and increased sensitivity
to PDGF and to gd-IgA. Thirdly, mucosal infections
(respiratory or intestinal) promote production of IgA
and trigger reactions including complement alterna-
tive and/or lectin pathway alterations [11]. The latter
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can explain both the chronic low-grade mesangial in-
flammation and the acute exacerbations with (macro-
scopic) hematuria, proteinuria and temporarily
elevated serum creatinine concentrations.
Conclusion
In conclusion, the mesangial cells of patients with IgA
nephropathy have a specialized phenotype and are more
reactive to PDGF and gd-IgA stimulation. The cells also
produce more PDGF. We believe one can say that at
least three factors are needed to develop IgAN; circulat-
ing IgA-complexes, activation of the complement system
[11], and a mesangial cell phenotype prone to respond
to IgA stimulation with proliferation and matrix
production.
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